Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this link

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
 Phase of development
 Approved
 Pre-registration & Phase III
 Phase II & Phase II/III

 Type of molecule
 Cell and gene therapies
 Monoclonal antibodies
 Proteins
 Peptides (recombinant)
 Vaccines
 Others

 Target therapeutic area
 Autoimmune disorders
 Blood disorders
 Bone disorders
 Genetic disorders
 Metabolic disorders
 Neurological disorders
 Oncological disorders
 Respiratory disorders
 Others

 Type of drug delivery system
 Large volume wearable injectors
 Autoinjectors
 Prefilled syringes
 Needle-free injectors
 Drug reconstitution systems

 Revenues from licensing deals
 Upfront payments
 Milestone payments

 Key geographical regions
 North America
 Europe
 Asia Pacific
 Rest of the World

The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
 Adocia
 Ajinomoto Bio-Pharma Services
 Arecor
 Alteogen
 Ascendis Pharma
 Avadel Pharmaceuticals
 Camurus
 Creative BioMart
 Creative Biolabs
 DURECT
 Eagle Pharmaceuticals
 Halozyme Therapeutics
 MedinCell
 Xeris Pharmaceuticals
 Serina Therapeutics

Table of Contents
1. Preface

2. Executive Summary

3. Introduction

4. Subcutaneous Biologics: Current Market Landscape

5. Case Study: Leading Subcutaneous Biologics

6. Subcutaneous Formulation Technologies: Current Market Landscape

7. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis

8. Subcutaneous Formulation Technology Developers: Company Profiles

9. Partnerships and Collaborations

10. Subcutaneous Drug Delivery Systems: Current Market Landscape

11. Swot Analysis

12. Market Forecast and Opportunity Analysis

13. Concluding Remarks

14. Executive Insights

15. Appendix 1: Tabulated Data

16. Appendix 2: List Of Companies And Organization


To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]